LeMaitre Vascular (LMAT) Stock Looks Priced Above Its Cash Flow Value

LeMaitre Vascular has seen its share price move in different directions over recent periods, and that raises a simple question for you as an investor: Is the current US$80.58 price tag supported by the cash flows the business can generate over time?

• Over the past 5 years the stock has returned 56.9%, which puts a lot of weight on whether those gains align with the cash the business can realistically produce.
• The company focuses on vascular devices and related procedures, which can influence expectations for future cash generation through pricing power, procedure volumes and how efficiently sales convert into free cash.
• Prefer to judge LeMaitre Vascular on earnings? See what LeMaitre Vascular's 28.1x P/E says about the price.

The issue now is whether the current share price is in line with what the Discounted Cash Flow (DCF) estimate suggests about LeMaitre Vascular's underlying cash flows.

If you are weighing LeMaitre Vascular purely on its cash flows, it can help to compare it with a focused list of other businesses screened for 30 high quality undervalued stocks.

Has LeMaitre Vascular Run Too Far on Cash Flow?

The Discounted Cash Flow (DCF) model used here projects what LeMaitre Vascular might return to shareholders in cash over time and then discounts those dollars back to today. On the latest figures, the business generated roughly $75.1 million of free cash flow over the last twelve months, which is the starting point for the valuation.

The DCF then assumes free cash flow grows gradually from that base, with analyst estimates and modelled figures pointing to a path of steady, mid sized annual cash generation rather than sharp swings. When that stream of projected cash flows is discounted and compared with the current share price of $80.58, the DCF projections put LeMaitre Vascular's estimated intrinsic value meaningfully below the current share price. Find out what LeMaitre Vascular could be worth using our Discounted Cash Flow (DCF) estimate.

The LeMaitre Vascular Narrative: What Would Justify Today's Price?

Narratives on LeMaitre Vascular pick up where the DCF puzzle leaves you. They spell out which combinations of future growth, profitability and earnings power would need to hold for the stock to be worth materially more or less than today’s price. They appear on Simply Wall St’s Community page as clear cases that each link a fair value estimate to a specific set of potential catalysts and risks, allowing you to track over time which version of the story is actually unfolding.

One of the top community narratives on LeMaitre Vascular: 27% undervalued

"Strong pipeline of biologics and next generation products, combined with ongoing regulatory wins, supports premium pricing and improved gross margins..."

Discover why this Narrative puts LeMaitre Vascular at 27% undervalued.

One more angle on LeMaitre Vascular that could change the story

Cash flows and valuation models only tell part of the story, because the people setting priorities and the way they are rewarded can heavily influence how those future dollars look. See who runs LeMaitre Vascular and how they are paid.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com